GlassScriptPhysician profile
Christopher S Carlin
NPI 1336186493
$8,631.65
in general payments reported to CMS, 2019-2025
31 companies · $1,716 in 2025
The $1,716 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,273 · 2020: $567 · 2021: $1,252 · 2022: $961 · 2023: $1,485 · 2024: $1,380 · 2025: $1,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,480 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,480.28 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,441.79 | 2019-2025 | Skyrizi, Rinvoq |
| Pfizer INC. | $910.10 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $710.28 | 2019-2025 | Libtayo, Dupixent |
| Galderma Laboratories, L.P. | $670.52 | 2019-2025 | Nemluvio, Dysport |
| Janssen Biotech, INC. | $663.17 | 2019-2025 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $629.85 | 2019-2025 | |
| Ucb, INC. | $480.84 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $452.10 | 2019-2025 | Adbry |
| Genzyme Corporation | $435.46 | 2019-2025 | |
| Lilly USA, LLC | $317.75 | 2019-2024 | Olumiant, Taltz, Ebglyss |
| Biofrontera INC. | $233.92 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Sun Pharmaceutical Industries INC. | $227.42 | 2019-2025 | Winlevi, Absorica Ld |
| Revance Therapeutics, INC. | $227.00 | 2025 | Daxxify |
| Amgen INC. | $190.42 | 2023-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $154.02 | 2023-2025 | Zoryve |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $147.83 | 2019-2024 | Cabtreo, Jublia, Arazlo |
| E.R. Squibb & Sons, L.L.C. | $115.34 | 2023-2024 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $105.42 | 2020-2021 | |
| Incyte Corporation | $105.08 | 2021-2024 | Opzelura |
| Dermira, INC. | $77.16 | 2019-2021 | |
| Almirall LLC | $63.96 | 2019-2025 | Klisyri |
| Medimetriks Pharmaceuticals, INC. | $37.48 | 2019-2020 | |
| Allergan, INC. | $37.14 | 2019 | |
| Mayne Pharma Commercial LLC | $32.58 | 2020 | |
| Vyne Pharmaceuticals INC. | $29.95 | 2020-2021 | |
| Merz North America, INC. | $28.63 | 2019 | |
| Celgene Corporation | $24.40 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $23.46 | 2019 | |
| Cipher Pharmaceuticals US LLC | $22.58 | 2025 | Natroba, Spinosad |
| Journey Medical Corporation | $21.33 | 2025 | |
| Lnhc, INC | $14.67 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Carlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.